Protagonist Therapeutics(PTGX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PTGX Protagonist Therapeutics

Not Yet Opened 04-01 16:00:00 EDT

103.67

-1.73

-1.64%

盘后103.67

+0.000.00%

19:21 EDT

High107.84	Low102.70	Vol583.87K
Open105.51	D1 Closing105.40	Amplitude4.88%
Mkt Cap6.62B	Tradable Cap4.47B	Total Shares63.81M
T/O60.88M	T/O Rate1.35%	Tradable Shares43.15M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PTGX","market":"US","secType":"STK","nameCN":"Protagonist Therapeutics","latestPrice":103.67,"timestamp":1775073600000,"preClose":105.4,"halted":0,"volume":583867,"hourTrading":{"tag":"盘后","latestPrice":103.67,"preClose":103.67,"latestTime":"19:21 EDT","volume":8460,"amount":877064.44,"timestamp":1775085701356,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01641366223908922,"floatShares":43154809,"shares":63808716,"eps":-2.05,"marketStatus":"Not Yet Opened","change":-1.73,"latestTime":"04-01 16:00:00 EDT","open":105.51,"high":107.84,"low":102.7,"amount":60879047.22423001,"amplitude":0.048767,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.05,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1775116800000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1470888000000,"exchange":"NASDAQ","adjPreClose":105.4,"preHourTrading":{"tag":"盘前","latestPrice":105.51,"preClose":105.4,"latestTime":"09:29 EDT","volume":1618,"amount":170619.57238,"timestamp":1775050199999,"change":0.11,"changeRate":0.001044,"amplitude":0.047438},"postHourTrading":{"tag":"盘后","latestPrice":103.67,"preClose":103.67,"latestTime":"19:21 EDT","volume":8460,"amount":877064.44,"timestamp":1775085701356,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.652765,"impliedVol":0.5181,"impliedVolPercentile":0.6096},"requestUrl":"/m/hq/s/PTGX","defaultTab":"news","newsList":[{"id":"2623334243","title":"Assessing Protagonist Therapeutics (PTGX) Valuation After Strong 1‑Year Shareholder Return","url":"https://stock-news.laohu8.com/highlight/detail?id=2623334243","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623334243?lang=en_us&edition=fundamental","pubTime":"2026-03-29 11:13","pubTimestamp":1774753987,"startTime":"0","endTime":"0","summary":"Why Protagonist Therapeutics Stock Is Drawing Attention Now\nProtagonist Therapeutics (PTGX) has been on investors’ radar after a recent share move, with the stock closing at US$98.97. Recent returns span a 7.5% gain over the past month and 12.6% over the past 3 months.\nSee our latest analysis for Protagonist Therapeutics.\nWhile the share price slipped 3.1% in the last session to US$98.97, the 30 day share price return of 7.5% and 12.6% over 90 days sit alongside a 1 year total shareholder...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/assessing-protagonist-therapeutics-ptgx-valuation-after-stro-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ptgx/protagonist-therapeutics/news/assessing-protagonist-therapeutics-ptgx-valuation-after-stro-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["PTGX","BK4139","DCF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622738492","title":"Protagonist says ICOTYDE Phase 3 one-year psoriasis data show durable skin clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=2622738492","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622738492?lang=en_us&edition=fundamental","pubTime":"2026-03-28 22:05","pubTimestamp":1774706729,"startTime":"0","endTime":"0","summary":"Protagonist disclosed one-year Phase 3 results for oral psoriasis drug ICOTYDE  were presented at 2026 American Academy of Dermatology annual meeting.Data from ICONIC-ADVANCE 1 and 2 showed durable complete skin clearance through Week 52, with PASI 100 rates rising from Week 24 to Week 52.Patients switching from placebo to ICOTYDE at Week 16 reached similar Week 52 clearance rates as continuous-treatment patients.ICONIC-LEAD adolescent study showed nearly 60% achieved completely clear skin at one year, with 86% reaching PASI 90.Approval of ICOTYDE in US triggers USD 50 million milestone payment to Protagonist, with eligibility for 6% to 10% tiered royalties on worldwide net sales.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260328:nNDL6XV6GV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622180265","title":"Protagonist Therapeutics Executives Quietly Cash In on Major Insider Stock Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2622180265","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622180265?lang=en_us&edition=fundamental","pubTime":"2026-03-28 10:02","pubTimestamp":1774663361,"startTime":"0","endTime":"0","summary":"New insider activity at Protagonist Therapeutics ( ($PTGX) ) has taken place on March 27, 2026. Insider activity at Protagonist Therapeutics has be...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/protagonist-therapeutics-executives-quietly-cash-in-on-major-insider-stock-sales-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/protagonist-therapeutics-executives-quietly-cash-in-on-major-insider-stock-sales-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622804136","title":"J&J Exits 3 Biotechs, Retains Stakes in 2 Possible Acquisitions -- Barron's","url":"https://stock-news.laohu8.com/highlight/detail?id=2622804136","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622804136?lang=en_us&edition=fundamental","pubTime":"2026-03-28 09:31","pubTimestamp":1774661460,"startTime":"0","endTime":"0","summary":"Johnson & Johnson's restated fourth-quarter holdings report, filed last week, reveals that the company exited three biotechs while retaining its stakes in several rumored acquisition targets.The changes included the sale of 247,598 shares in Arrowhead Pharmaceuticals, previously a partner of Johnson & Johnson's Janssen unit, which rebranded as its Innovative Medicine division. The relationship came to an end in 2023 after Janssen shrunk its infectious disease and vaccine portfolios.Johnson & Johnson also exited BiomX, another former collaborator, through the sale of 96,866 shares. The Israeli biotech in December suddenly halted its lead clinical program due to safety concerns, and has been restructuring since.Also in the fourth quarter, Johnson & Johnson unloaded 54,621 shares of Senseonics Holdings to close out its stake in the medical technology maker.Other holdings went unchanged, including Johnson & Johnson's stake of 814,586 shares in Legend Biotech. The companies have an agreemen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1430594728.SGD","LU1244550494.USD","IE00BLSP4452.SGD","LU2129689431.USD","SG9999002232.USD","IE00BLSP4239.USD","LU0289739699.SGD","LU2602419157.SGD","LU2129689605.HKD","LU1267930813.SGD","LU1732799900.SGD","LU0345770993.USD","LU2471134523.USD","LU1023059063.AUD","IE00BBT3K403.USD","LU0345770308.USD","LU1929549753.HKD","LU0912757837.SGD","LU0122379950.USD","LU2129689514.USD","IE00BFTCPJ56.SGD","PHGE","IE00B4R5TH58.HKD","PTGX","LEGN","LU0203345920.USD","LU0689626769.HKD","LU0640476718.USD","IE0001KFT4U8.USD","BK4504","LU0432979614.USD","LU0787776722.HKD","IE00BJJMRZ35.SGD","BK4581","ARWR","LU1280957306.USD","LU2089984988.USD","LU2471134796.USD","LU1059921491.USD","LU1196500208.SGD","LU1674673428.USD","IE00B19Z3581.USD","LU0058720904.USD","LU0985320562.USD","BK4533","LU0466842654.USD","LU2592432038.USD","LU0124676726.USD","IE00BKVL7J92.USD","JNJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622686809","title":"Protagonist Therapeutics; Chief Medical Officer Arturo Molina disposes of 15,000 common shares valued at $1,572,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2622686809","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622686809?lang=en_us&edition=fundamental","pubTime":"2026-03-28 07:36","pubTimestamp":1774654614,"startTime":"0","endTime":"0","summary":"Arturo Molina, Chief Medical Officer at Protagonist Therapeutics, reported transactions in the company’s common stock dated 03/26/2026.Molina acquired 15,000 shares at USD 8.04 per share through an option exercise.He sold 15,000 shares at a weighted average price of USD 104.79 per share.Following the transactions, Molina reported direct ownership of 84,115 common shares.He also reported direct ownership of 50,971 stock options after the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagonist Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 27, 2026, ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL2nB5tg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622096838","title":"Protagonist Therapeutics director Harold E. Selick disposes of 24,000 common shares; value drops to $2,520,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2622096838","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622096838?lang=en_us&edition=fundamental","pubTime":"2026-03-28 07:35","pubTimestamp":1774654515,"startTime":"0","endTime":"0","summary":"Harold Selick, a director at Protagonist Therapeutics, reported exercising stock options for 24,000 common shares at USD 12.88 per share on 03/26/2026.He also reported selling 24,000 common shares at USD 105 per share on 03/26/2026.After the reported transactions, Selick beneficially owned 60,845 common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagonist Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL7yqpkp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622480951","title":"Protagonist Therapeutics CFO Ali Asif disposes of common shares; sale totals $2,581,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2622480951","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622480951?lang=en_us&edition=fundamental","pubTime":"2026-03-28 07:34","pubTimestamp":1774654482,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics Chief Financial Officer Ali Asif reported option exercises for 19,500 shares at USD 19.19 per share.He also exercised options for 5,265 shares at USD 12.17 per share.Asif sold 24,765 shares at a weighted average price of USD 104.24 per share.Following the transactions, he beneficially owned 60,753 shares of common stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagonist Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 27, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL5pZ3s6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Protagonist Therapeutics CFO Ali Asif disposes of common shares; sale totals $2,581,000","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622883674","title":"Protagonist Therapeutics President and CEO Dinesh V. Patel disposes of 54,700 common shares; value drops to $5,524,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2622883674","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622883674?lang=en_us&edition=fundamental","pubTime":"2026-03-26 07:23","pubTimestamp":1774481026,"startTime":"0","endTime":"0","summary":"Dinesh Patel, President and CEO of Protagonist Therapeutics, reported a gift disposition of 50,000 common shares on 03/23/2026.He reported exercising stock options for 59 shares at USD 8.58 per share on 03/24/2026.The same day, he sold 59 common shares at USD 101 per share.He exercised stock options for 54,641 shares at USD 8.58 per share on 03/25/2026.Following the reported transactions, he beneficially owned 524,938 common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagonist Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 25, 2026, and is solely res","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL3wjtQg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Protagonist Therapeutics President and CEO Dinesh V. Patel disposes of 54,700 common shares; value drops to $5,524,000","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621477192","title":"Analysts Are Bullish on Top Healthcare Stocks: Protagonist Therapeutics (PTGX), MDxHealth (MDXH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2621477192","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621477192?lang=en_us&edition=fundamental","pubTime":"2026-03-23 17:30","pubTimestamp":1774258225,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Protagonist Therapeutics (PTGX) and MDxHealth (MDXH)...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-protagonist-therapeutics-ptgx-mdxhealth-mdxh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-protagonist-therapeutics-ptgx-mdxhealth-mdxh-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","XBI","LU0029874061.USD","BLSG","BK4585","PTGX","BK4137","BK4588","BK4139","BK4112","LU0128526141.USD","BLSX","MDXH","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620222798","title":"Protagonist's Oral Peptide Platform Validated With Icotyde Approval for Psoriasis, Wedbush Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2620222798","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620222798?lang=en_us&edition=fundamental","pubTime":"2026-03-20 00:10","pubTimestamp":1773936659,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics  received further validation for its oral peptide platform with the US Food Drug Administration approval of Icotyde as treatment for psoriasis, Wedbush Securities said in a note Thursday.The investment firm said the regulatory approval was expected after Protagonist and partner Johnson & Johnson , which holds global rights to commercialize Icotyde, reported \"compelling\" phase 3 results.Wedbush said it made adjustments based on what it sees as a \"favorable label,\" and now models a target population of patients 12 years and older while increasing its market penetration forecast for Icotyde.Icotyde's approval is expected to positively impact Protagonist's other clinical programs, which are already attracting \"strong\" partnership interest, according to the note.Wedbush raised its price target to $112 from $100, and reiterated its outperform rating on the stock.Protagonist shares were up 7.6% in midday trading Thursday.Price: 104.50, Change: +7.41, Percent Change: +","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE000M9KFDE8.USD","BK4588","BK4139","IE0002270589.USD","IE00BLSP4452.SGD","LU0058720904.USD","LU0203347892.USD","LU2750360641.GBP","BK4504","IE00B19Z3B42.SGD","LU1244550577.SGD","LU1162221912.USD","LU2112291526.USD","LU1914381329.SGD","LU0320765646.SGD","LU1674673691.USD","IE0001KFT4U8.USD","LU1267930813.SGD","IE00B42XCP33.USD","LU1585245621.USD","PTGX","IE0034235303.USD","LU1280957306.USD","LU0345769631.USD","IE0009355771.USD","LU0985320562.USD","IE00BZ1G4Q59.USD","LU1061106388.HKD","LU0345770308.USD","LU1244550221.USD","LU1023059063.AUD","LU1066051811.HKD","BK4559","JNJ","LU0070217475.USD","LU0787776722.HKD","LU0124676726.USD","LU1066053197.SGD","LU1732799900.SGD","LU2129689514.USD","IE00BGHQF631.EUR","LU1059921491.USD","LU2133065610.SGD","BK4568","IE00BFXG1179.USD","LU1244550494.USD","LU2430703251.USD","LU1057294990.SGD","LU1221951046.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620222133","title":"Protagonist price target raised to $110 from $107 at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2620222133","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620222133?lang=en_us&edition=fundamental","pubTime":"2026-03-19 23:41","pubTimestamp":1773934874,"startTime":"0","endTime":"0","summary":"Leerink analyst Faisal Khurshid raised the firm’s price target on Protagonist Therapeutics (PTGX) to $110 from $107 and keeps an Outperform rating ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/protagonist-price-target-raised-to-110-from-107-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/protagonist-price-target-raised-to-110-from-107-at-leerink-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620221130","title":"Protagonist Therapeutics Is Maintained at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2620221130","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620221130?lang=en_us&edition=fundamental","pubTime":"2026-03-19 22:47","pubTimestamp":1773931620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PTGX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 19, 2026 10:47 ET (14:47 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620228170","title":"Johnson & Johnson-Protagonist Therapeutics Partnered New Psoriasis Pill Wins FDA Nod, Shakes Up Competition With AbbVie","url":"https://stock-news.laohu8.com/highlight/detail?id=2620228170","media":"Benzinga_recent_news","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620228170?lang=en_us&edition=fundamental","pubTime":"2026-03-19 20:25","pubTimestamp":1773923100,"startTime":"0","endTime":"0","summary":"FDA approves Icotyde, a once-daily psoriasis pill from Johnson & Johnson, sparking new competition in treatment options.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/19/Exterior-Shot-Of-The-Johnson-Johnson-Cor.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/19/Exterior-Shot-Of-The-Johnson-Johnson-Cor.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/fda/26/03/51351350/johnson-johnson-protagonist-therapeutics-partnered-new-psoriasis-pill-wins-fda-nod-shakes-up-competition-with-abbvie","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/fda/26/03/51351350/johnson-johnson-protagonist-therapeutics-partnered-new-psoriasis-pill-wins-fda-nod-shakes-up-competition-with-abbvie","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0795875169.SGD","LU0472753341.HKD","LU0949170772.SGD","ABBV","LU0198837287.USD","LU0289739343.SGD","LU0098860793.USD","IE00B2B36J28.USD","LU1674673691.USD","SG9999011175.SGD","LU2471134879.HKD","IE00BJJMRZ35.SGD","LABU","LU1032955483.USD","LU0256863811.USD","PTGX","LU1003077747.HKD","LU1267930573.SGD","SG9999001440.SGD","SG9999015945.SGD","LU0511384066.AUD","LU2089984988.USD","LU1280957306.USD","LU2347655156.SGD","LU0256863902.USD","LU1989772840.SGD","LU2471134523.USD","LU0345770308.USD","LU1506573853.SGD","LU1674673428.USD","LU1244550221.USD","LU0965509010.AUD","LU0289961442.SGD","JNJ","LU1732799900.SGD","LU1935042991.SGD","LU0124676726.USD","LU2237443549.SGD","IE00BFTCPJ56.SGD","LU2023251221.USD","LU1196500208.SGD","BK4568","BK4533","LU1839511570.USD","IE00B19Z3581.USD","BK4585","LU0640476718.USD","LU0211328371.USD","BK4581","LU2505996509.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620724226","title":"Wedbush Raises Price Target on Protagonist Therapeutics to $112 From $100, Keeps Outperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2620724226","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620724226?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:42","pubTimestamp":1773920562,"startTime":"0","endTime":"0","summary":"Protagonist Therapeutics (PTGX) has an average rating of buy and mean price target of $92.56, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620426842","title":"Protagonist Therapeutics Inc : Wedbush Raises Target Price to $112 From $100","url":"https://stock-news.laohu8.com/highlight/detail?id=2620426842","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620426842?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:30","pubTimestamp":1773919843,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nFWN4070Y1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620241859","title":"Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK), Valneva (VALN) and Protagonist Therapeutics (PTGX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620241859","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620241859?lang=en_us&edition=fundamental","pubTime":"2026-03-19 18:20","pubTimestamp":1773915610,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Stoke Therapeutics (STOK), Valneva (VALN) and Protag...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-stoke-therapeutics-stok-valneva-valn-and-protagonist-therapeutics-ptgx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-stoke-therapeutics-stok-valneva-valn-and-protagonist-therapeutics-ptgx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","HCSG","LU0029874061.USD","PTGX","BK4137","BK4539","BK4585","VALN","BK4588","LU0128526141.USD","LABU","STOK","XLV","BK4581","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620245285","title":"Protagonist Therapeutics price target raised to $119 from $113 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2620245285","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620245285?lang=en_us&edition=fundamental","pubTime":"2026-03-19 17:30","pubTimestamp":1773912628,"startTime":"0","endTime":"0","summary":"Barclays raised the firm’s price target on Protagonist Therapeutics (PTGX) to $119 from $113 and keeps an Overweight rating on the shares. The FDA ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/protagonist-therapeutics-price-target-raised-to-119-from-113-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/protagonist-therapeutics-price-target-raised-to-119-from-113-at-barclays-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620248311","title":"Protagonist Therapeutics (PTGX) Receives a Buy from Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2620248311","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620248311?lang=en_us&edition=fundamental","pubTime":"2026-03-19 16:36","pubTimestamp":1773909387,"startTime":"0","endTime":"0","summary":"In a report released today, Etzer Darout from Barclays maintained a Buy rating on Protagonist Therapeutics, with a price target of $119.00. Darout ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/protagonist-therapeutics-ptgx-receives-a-buy-from-barclays-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/protagonist-therapeutics-ptgx-receives-a-buy-from-barclays-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTGX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620266277","title":"Protagonist Therapeutics price target raised to $104 from $91 at Clear Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2620266277","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620266277?lang=en_us&edition=fundamental","pubTime":"2026-03-19 02:05","pubTimestamp":1773857134,"startTime":"0","endTime":"0","summary":"Clear Street raised the firm’s price target on Protagonist Therapeutics (PTGX) to $104 from $91 and keeps a Buy rating on the shares following the ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/protagonist-therapeutics-price-target-raised-to-104-from-91-at-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/protagonist-therapeutics-price-target-raised-to-104-from-91-at-clear-street-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTGX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620057265","title":"BUZZ-U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2620057265","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620057265?lang=en_us&edition=fundamental","pubTime":"2026-03-19 01:49","pubTimestamp":1773856151,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi TechnologiesWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning N","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nL6N4060ZF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SOFI","STZ","GEMI","MMED","WAL","SABS","CRC","CDE","TTD","ORA","ARTL","ABBV","OVID","DOCU","LNTH","LEN","HL","NEM","DUOL","MTVA","CTMX","NSPR","PTGX","ARVN","VRTX","BMRA","XYZ","USEG","SLG","FICO","SAIL","APD","GIS","RNXT","ISRG","TE","LCID","KNX","ARES","SBUX"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.protagonist-inc.com","stockEarnings":[{"period":"1week","weight":-0.0061},{"period":"1month","weight":0.1001},{"period":"3month","weight":0.187},{"period":"6month","weight":0.5991},{"period":"1year","weight":1.2114},{"period":"ytd","weight":0.187}],"compareEarnings":[{"period":"1week","weight":-0.0024},{"period":"1month","weight":-0.0454},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0209},{"period":"1year","weight":0.168},{"period":"ytd","weight":-0.0391}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.030975},{"month":2,"riseRate":0.5,"avgChangeRate":0.004927},{"month":3,"riseRate":0.5,"avgChangeRate":0.077907},{"month":4,"riseRate":0.2,"avgChangeRate":-0.114341},{"month":5,"riseRate":0.666667,"avgChangeRate":0.20629},{"month":6,"riseRate":0.777778,"avgChangeRate":0.09374},{"month":7,"riseRate":0.555556,"avgChangeRate":0.002773},{"month":8,"riseRate":0.777778,"avgChangeRate":0.16209},{"month":9,"riseRate":0.5,"avgChangeRate":0.00523},{"month":10,"riseRate":0.4,"avgChangeRate":0.039581},{"month":11,"riseRate":0.6,"avgChangeRate":0.076941},{"month":12,"riseRate":0.5,"avgChangeRate":0.014044}],"exchange":"NASDAQ","name":"Protagonist Therapeutics","nameEN":"Protagonist Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Protagonist Therapeutics(PTGX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Protagonist Therapeutics(PTGX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Protagonist Therapeutics,PTGX,Protagonist Therapeutics股票,Protagonist Therapeutics股票老虎,Protagonist Therapeutics股票老虎国际,Protagonist Therapeutics行情,Protagonist Therapeutics股票行情,Protagonist Therapeutics股价,Protagonist Therapeutics股市,Protagonist Therapeutics股票价格,Protagonist Therapeutics股票交易,Protagonist Therapeutics股票购买,Protagonist Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Protagonist Therapeutics(PTGX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Protagonist Therapeutics(PTGX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}